XORTX Therapeutics Inc. (NASDAQ: XRTX)
$1.2300
+0.0100 ( +0.82% ) 7.7K
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
Market Data
Open
$1.2300
Previous close
$1.2200
Volume
7.7K
Market cap
$3.93M
Day range
$1.2150 - $1.3190
52 week range
$1.0900 - $7.0000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Form 6-K | 2 | Jun 12, 2024 |
6-k | Form 6-K | 2 | Jun 04, 2024 |
6-k | Form 6-K | 2 | May 20, 2024 |
6-k | Form 6-K | 6 | May 17, 2024 |
20-f | Annual reports | 115 | May 10, 2024 |
nt | Quarterly Reports | 1 | May 01, 2024 |
6-k | Form 6-K | 2 | Apr 30, 2024 |
6-k | Form 6-K | 2 | Apr 22, 2024 |
6-k | Form 6-K | 2 | Apr 08, 2024 |
6-k | Form 6-K | 2 | Apr 08, 2024 |